Does a nanomolecule of Carboplatin injected periocularly help in attaining higher intravitreal concentrations?
Nanoparticulate-bound carboplatin has greater transscleral transport than commercially available carboplatin, especially in the first week after injection and may help enhance the proven adjuvant efficacy of periocular carboplatin over and above systemic chemotherapy in treating human retinoblastoma, especially those with vitreal seeds. This trial is being published to establish a proof of principle for this method of therapy.
Methicillin-resistant Staphylococcus aureus infection does not represent a significant source of morbidity in our practice.